MCP-1与绝经激素治疗对心血管保护作用的研究进展

Monocyte Chemoattractant Protein-1 and Menopause Hormone Therapy′ s Cardiovascular Protective Effect

多种疾病,包括心血管疾病,被广泛认为是炎症性疾病。许多细胞因子和趋化因子参与心血管疾病的病理生理过程。绝经的本质是卵巢功能的衰竭,机体雌激素的缺乏,导致糖脂代谢异常,炎症因子失衡,机体处于慢性炎症状态。单核细胞趋化蛋白1(monocyte chemoattractant protein-1,MCP-1)可诱导、调节其他炎性因子的形成和释放,形成级联反应,介导炎症反应,因此MCP-1被认为是炎症反应的启动因子。MCP-1趋化单核细胞在内皮下聚集,转变成泡沫细胞,导致脂肪纹及动脉粥样硬化斑块的形成,被认为是动脉粥样硬化的关键因子。有研究表明,绝经激素治疗(menopause hormone therapy,MHT)可下调绝经女性血清MCP-1水平,从而发挥心血管保护作用。综述MCP-1与MHT的研究现况,特别是MCP-1与MHT的心血管保护作用研究进展。

A variety of diseases, including cardiovascular disease, are widely recognized as inflammatory diseases. Many cytokines and chemokines are involved in the pathological processes of cardiovascular disease. Menopause is estrogen＇s deficiency, which leads to the glucolipid metabolic abnormality, inflammatory factors＇ imbalance, the state of chronic inflammation. Monocyte chemoattractant protein-1（MCP-1） induces and regulates the formation and release of other inflammatory cytokines, mediating inflammation, therefore is considered as the start of the inflammatory factor. MCP-1chemokines monocyte from the lumen to the subendothelial space, initiating foam cells and fatty streak formation that leads to atherosclerotic plaque formation, which is considered to be the key factor of atherosclerosis. Research has shown that menopause hormone therapy（MHT） can down regulate the level of postmenopausal women serum MCP-1,so as to exert its effect of cardiovascular protection. MCP-1 and the cardiovascular protective effect of MHT will be summarized.